Related Experiment Video
Updated: Jun 23, 2026
04:36
Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis
Published on: October 2, 2020
Spironolactone in chronic hemodialysis patients improves cardiac function
Shahram Taheri1, Mojhgan Mortazavi, Shahrzad Shahidi
1Department of Internal Medicine, Isfahan School of Medicine, Iran. shah63tah@yahoo.com
Summary
Low-dose spironolactone significantly improved cardiac function and reduced left ventricular mass in hemodialysis patients with heart failure. This treatment did not increase the risk of hyperkalemia, offering a potential new therapy.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Heart failure is a common complication in patients undergoing chronic hemodialysis (HD).
- Mineralocorticoid receptor antagonists like spironolactone can improve cardiovascular outcomes but carry a risk of hyperkalemia, especially in HD patients.
Purpose of the Study:
- To evaluate the efficacy and safety of low-dose spironolactone in improving cardiovascular function in hemodialysis patients with moderate to severe heart failure.
- To assess the impact of spironolactone on left ventricular mass and hospitalization rates.
- To determine if spironolactone administration increases the risk of hyperkalemia in this patient population.
Main Methods:
- A double-blind, randomized, placebo-controlled study involving 16 chronic HD patients with ejection fraction ≤45% and moderate to severe heart failure.
- Patients received either 25 mg spironolactone or placebo after each dialysis session for six months.
- Echocardiography assessed ejection fraction and left ventricular mass; serum potassium was monitored regularly.
Main Results:
- Spironolactone significantly increased ejection fraction compared to placebo (6.2% vs. 0.83%, P=0.046).
- Left ventricular mass decreased in the spironolactone group, while it increased in the placebo group (P=0.021).
- No significant increase in hyperkalemia incidence was observed in the spironolactone group.
Conclusions:
- Low-dose spironolactone is effective in improving cardiac function and reducing left ventricular mass in hemodialysis patients with heart failure.
- Spironolactone can be safely administered in this population without a significant increase in hyperkalemia.
- This suggests spironolactone is a promising therapeutic option for heart failure in chronic hemodialysis patients.
Related Concept Videos
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:25Hemodialysis III: Nursing Management
The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this measurement...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:24Hemodialysis II: Procedure and Complications
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...